MedTrace Logo

Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study)

NCT00790946 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2010-06-03

No results posted yet for this study

Summary

The purpose of this study is to consider the following points in patients with hypertension who complicated by metabolic syndrome for Valsartan basis treatment and an existing, standard treatment.

* Blood pressure control
* Changing of adiponectin and plasminogen activator inhibitor-1
* Influence metabolizing and cardiac function, etc.

Conditions

Interventions

DRUG

Valsartan

Valsartan 80 to 160 mg

Sponsors & Collaborators

  • Kagoshima University

    lead OTHER

Principal Investigators

  • Chuwa Tei, MD, PhD · Department of Cardiovascular,Respiratory & Metabolic Medicine Granduate School of Medicine Kagoshima University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00790946 on ClinicalTrials.gov